Kogavant

Ticagrelor, the active ingredient in Kogavant, is a P2Y12 receptor antagonist presented as an oral tablet for oral use. It is indicated for the management of acute coronary syndrome, including ST-elevation myocardial infarction, non‑ST‑elevation myocardial infarction and unstable angina in adult patients.

GNH USA supplies Kogavant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kogavant (ticagrelor) is used to reduce thrombotic cardiovascular events in the acute coronary syndrome pathway.

- Acute coronary syndrome: lowers the risk of cardiovascular death, myocardial infarction and stroke. - ST-elevation myocardial infarction (STEMI): improves outcomes when used with percutaneous coronary intervention. - Non‑ST-elevation myocardial infarction (NSTEMI): reduces recurrent ischemic events. - Unstable angina: decreases the incidence of subsequent myocardial infarction and urgent revascularisation.

Ticagrelor may be associated with a range of adverse reactions, which are classified by frequency.

Common Side Effects: - Dyspnea - Headache - Nausea - Minor bleeding (e.g., bruising, gum bleeding) - Dizziness

Serious or Rare Side Effects: - Severe or life‑threatening bleeding - Intracranial hemorrhage - Myocardial infarction recurrence - Hepatic injury - Anaphylactic or severe allergic reactions - Thrombocytopenia

When prescribing Kogavant, clinicians should consider the following precautions.

- Bleeding risk assessment: evaluate for active or recent bleeding before initiation. - Respiratory monitoring: observe for new or worsening dyspnea. - Hepatic function: check liver enzymes in patients with hepatic impairment. - Renal function: adjust use in severe renal impairment as recommended. - Concomitant antithrombotic therapy: avoid use with other potent antiplatelet or anticoagulant agents unless clinically justified. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Kogavant can interact with several medicines, requiring avoidance or careful monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ticagrelor exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Co‑administration with other potent antiplatelet agents (e.g., prasugrel) without clinical need.

Moderate Interactions (Monitor Closely): - NSAIDs: increase risk of gastrointestinal bleeding. - Selective serotonin reuptake inhibitors (SSRIs): may enhance bleeding tendency. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): require close monitoring of coagulation parameters. - Statins metabolized by CYP3A4 (e.g., simvastatin): may raise statin levels.